Utah Code 26B-3-105. Medicaid drug program — Preferred drug list
Current as of: 2024 | Check for updates
|
Other versions
(1) A Medicaid drug program developed by the department under Subsection 26B-3-104(2)(f):
Terms Used In Utah Code 26B-3-105
- Evidence: Information presented in testimony or in documents that is used to persuade the fact finder (judge or jury) to decide the case for one side or the other.
- Medicaid program: means the state program for medical assistance for persons who are eligible under the state plan adopted pursuant to Title XIX of the federal Social Security Act. See Utah Code 26B-3-101
- Process: means a writ or summons issued in the course of a judicial proceeding. See Utah Code 68-3-12.5
- State: when applied to the different parts of the United States, includes a state, district, or territory of the United States. See Utah Code 68-3-12.5
- Trial: A hearing that takes place when the defendant pleads "not guilty" and witnesses are required to come to court to give evidence.
- Writing: includes :(48)(a) printing;(48)(b) handwriting; and(48)(c) information stored in an electronic or other medium if the information is retrievable in a perceivable format. See Utah Code 68-3-12.5(1)(a) shall, notwithstanding Subsection 26B-3-104(1)(b), be based on clinical and cost-related factors which include medical necessity as determined by a provider in accordance with administrative rules established by the Drug Utilization Review Board;(1)(b) may include therapeutic categories of drugs that may be exempted from the drug program;(1)(c) may include placing some drugs, except the drugs described in Subsection (2), on a preferred drug list:(1)(c)(i) to the extent determined appropriate by the department; and(1)(c)(ii) in the manner described in Subsection (3) for psychotropic drugs;(1)(d) notwithstanding the requirements of Sections 26B-3-302 through 26B-3-309 regarding the Drug Utilization Review Board, and except as provided in Subsection (3), shall immediately implement the prior authorization requirements for a nonpreferred drug that is in the same therapeutic class as a drug that is:(1)(d)(i) on the preferred drug list on the date that this act takes effect; or(1)(d)(ii) added to the preferred drug list after this act takes effect; and(1)(e) except as prohibited by Subsections 58-17b-606(4) and (5), shall establish the prior authorization requirements established under Subsections (1)(c) and (d) which shall permit a health care provider or the health care provider’s agent to obtain a prior authorization override of the preferred drug list through the department’s pharmacy prior authorization review process, and which shall:(1)(e)(i) provide either telephone or fax approval or denial of the request within 24 hours of the receipt of a request that is submitted during normal business hours of Monday through Friday from 8 a.m. to 5 p.m.;(1)(e)(ii) provide for the dispensing of a limited supply of a requested drug as determined appropriate by the department in an emergency situation, if the request for an override is received outside of the department’s normal business hours; and(1)(e)(iii) require the health care provider to provide the department with documentation of the medical need for the preferred drug list override in accordance with criteria established by the department in consultation with the Pharmacy and Therapeutics Committee.
(2)
(2)(a) As used in this Subsection (2):
(2)(a)(i) “Immunosuppressive drug”:
(2)(a)(i)(A) means a drug that is used in immunosuppressive therapy to inhibit or prevent activity of the immune system to aid the body in preventing the rejection of transplanted organs and tissue; and
(2)(a)(i)(B) does not include drugs used for the treatment of autoimmune disease or diseases that are most likely of autoimmune origin.
(2)(a)(ii) “Stabilized” means a health care provider has documented in the patient’s medical chart that a patient has achieved a stable or steadfast medical state within the past 90 days using a particular psychotropic drug.
(2)(b) A preferred drug list developed under the provisions of this section may not include an immunosuppressive drug.
(2)(c)
(2)(c)(i) The state Medicaid program shall reimburse for a prescription for an immunosuppressive drug as written by the health care provider for a patient who has undergone an organ transplant.
(2)(c)(ii) For purposes of Subsection 58-17b-606(4), and with respect to patients who have undergone an organ transplant, the prescription for a particular immunosuppressive drug as written by a health care provider meets the criteria of demonstrating to the department a medical necessity for dispensing the prescribed immunosuppressive drug.
(2)(d) Notwithstanding the requirements of Sections 26B-3-302 through 26B-3-309 regarding the Drug Utilization Review Board, the state Medicaid drug program may not require the use of step therapy for immunosuppressive drugs without the written or oral consent of the health care provider and the patient.
(2)(e) The department may include a sedative hypnotic on a preferred drug list in accordance with Subsection (2)(f).
(2)(f) The department shall grant a prior authorization for a sedative hypnotic that is not on the preferred drug list under Subsection (2)(e), if the health care provider has documentation related to one of the following conditions for the Medicaid client:
(2)(f)(i) a trial and failure of at least one preferred agent in the drug class, including the name of the preferred drug that was tried, the length of therapy, and the reason for the discontinuation;
(2)(f)(ii) detailed evidence of a potential drug interaction between current medication and the preferred drug;
(2)(f)(iii) detailed evidence of a condition or contraindication that prevents the use of the preferred drug;
(2)(f)(iv) objective clinical evidence that a patient is at high risk of adverse events due to a therapeutic interchange with a preferred drug;
(2)(f)(v) the patient is a new or previous Medicaid client with an existing diagnosis previously stabilized with a nonpreferred drug; or
(2)(f)(vi) other valid reasons as determined by the department.
(2)(g) A prior authorization granted under Subsection (2)(f) is valid for one year from the date the department grants the prior authorization and shall be renewed in accordance with Subsection (2)(f).
(3)
(3)(a) As used in this Subsection (3), “psychotropic drug” means the following classes of drugs:
(3)(a)(i) atypical anti-psychotic;
(3)(a)(ii) anti-depressant;
(3)(a)(iii) anti-convulsant/mood stabilizer;
(3)(a)(iv) anti-anxiety; and
(3)(a)(v) attention deficit hyperactivity disorder stimulant.
(3)(b)
(3)(b)(i) The department shall develop a preferred drug list for psychotropic drugs.
(3)(b)(ii) Except as provided in Subsection (3)(d), a preferred drug list for psychotropic drugs developed under this section shall allow a health care provider to override the preferred drug list by writing “dispense as written” on the prescription for the psychotropic drug.
(3)(b)(iii) A health care provider may not override Section 58-17b-606 by writing “dispense as written” on a prescription.
(3)(c) The department, and a Medicaid accountable care organization that is responsible for providing behavioral health, shall:
(3)(c)(i) establish a system to:
(3)(c)(i)(A) track health care provider prescribing patterns for psychotropic drugs;
(3)(c)(i)(B) educate health care providers who are not complying with the preferred drug list; and
(3)(c)(i)(C) implement peer to peer education for health care providers whose prescribing practices continue to not comply with the preferred drug list; and
(3)(c)(ii) determine whether health care provider compliance with the preferred drug list is at least:
(3)(c)(ii)(A) 55% of prescriptions by July 1, 2017;
(3)(c)(ii)(B) 65% of prescriptions by July 1, 2018; and
(3)(c)(ii)(C) 75% of prescriptions by July 1, 2019.
(3)(d) Beginning October 1, 2019, the department shall eliminate the dispense as written override for the preferred drug list, and shall implement a prior authorization system for psychotropic drugs, in accordance with Subsection (2)(f), if by July 1, 2019, the department has not realized annual savings from implementing the preferred drug list for psychotropic drugs of at least $750,000 General Fund savings.